STOCK TITAN

[SCHEDULE 13G/A] Immunocore Holdings plc American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing: Schedule 13G/A (Amendment No. 5) reporting for Immunocore Holdings plc (CUSIP 45258D105).

Key facts: Wellington Management Group LLP and affiliated entities report beneficial ownership of 5,132,898 shares of Immunocore common stock (reported as 10.2% / 10.22% of the class). Reported ownership shows no sole voting or dispositive power; shared voting power is reported as 4,958,998 and shared dispositive power as 5,132,898. The filing notes these shares are owned of record by clients of Wellington investment advisers and identifies Vanguard Health Care Fund as an exception referenced in Item 6. The issuer address and filer addresses are included; the filing is signed by Taisia Lowe on 08/05/2025.

Deposito: Schedule 13G/A (Emendamento n. 5) relativo a Immunocore Holdings plc (CUSIP 45258D105).

Fatti principali: Wellington Management Group LLP e entità affiliate dichiarano la detenzione effettiva di 5.132.898 azioni di Immunocore common stock (riportate come 10,2% / 10,22% della classe). La proprietà dichiarata non indica potere di voto o di disposizione esclusivo; il potere di voto condiviso è indicato come 4.958.998 e il potere di disposizione condiviso come 5.132.898. La segnalazione precisa che queste azioni sono intestate a clienti dei consulenti d'investimento di Wellington e identifica il Vanguard Health Care Fund come eccezione citata nell'Elemento 6. Sono incluse le indirizzi dell'emittente e dei soggetti che presentano il documento; il deposito è firmato da Taisia Lowe in data 08/05/2025.

Presentación: Schedule 13G/A (Enmienda n.º 5) relativa a Immunocore Holdings plc (CUSIP 45258D105).

Datos clave: Wellington Management Group LLP y entidades afiliadas informan la propiedad beneficiaria de 5.132.898 acciones de las acciones ordinarias de Immunocore (reportadas como 10,2% / 10,22% de la clase). La propiedad declarada no muestra poder exclusivo de voto ni de disposición; se informa poder de voto compartido de 4.958.998 y poder de disposición compartido de 5.132.898. La presentación indica que estas acciones están registradas a nombre de clientes de los asesores de inversión de Wellington y identifica a Vanguard Health Care Fund como excepción referida en el Punto 6. Se incluyen las direcciones del emisor y de los presentadores; la presentación está firmada por Taisia Lowe el 08/05/2025.

제출: Schedule 13G/A (Amendment No. 5) — Immunocore Holdings plc에 대한 신고 (CUSIP 45258D105).

주요 사항: Wellington Management Group LLP 및 계열사는 Immunocore 보통주 5,132,898주를 실질적으로 보유하고 있다고 보고(해당 등급의 10.2% / 10.22%로 보고됨). 보고된 보유는 단독 의결권 또는 단독 처분권이 없음을 표시하며, 공동 의결권은 4,958,998주, 공동 처분권은 5,132,898주로 보고됩니다. 제출서에는 이 주식들이 웰링턴 투자 자문사의 고객 명의로 등기되어 있다고 기재되어 있으며, Item 6에 언급된 예외로 Vanguard Health Care Fund가 식별되어 있습니다. 발행인 주소 및 제출인 주소가 포함되어 있고; 제출서는 Taisia Lowe가 08/05/2025에 서명했습니다.

Dépôt : Schedule 13G/A (Amendement n° 5) concernant Immunocore Holdings plc (CUSIP 45258D105).

Faits clés : Wellington Management Group LLP et entités affiliées déclarent une participation bénéficiaire de 5 132 898 actions d'actions ordinaires d'Immunocore (déclarée comme 10,2% / 10,22% de la catégorie). La participation déclarée n'indique aucun pouvoir exclusif de vote ni de disposition ; le pouvoir de vote partagé est indiqué à 4 958 998 et le pouvoir de disposition partagé à 5 132 898. Le dépôt précise que ces actions sont inscrites au nom de clients des conseillers en investissement de Wellington et identifie le Vanguard Health Care Fund comme exception mentionnée à l'Item 6. Les adresses de l'émetteur et des déclarants sont incluses ; le dépôt est signé par Taisia Lowe le 08/05/2025.

Einreichung: Schedule 13G/A (Amendment Nr. 5) für Immunocore Holdings plc (CUSIP 45258D105).

Wesentliche Angaben: Wellington Management Group LLP und verbundene Einheiten melden wirtschaftliches Eigentum an 5.132.898 Aktien der Immunocore-Stammaktien (angegeben als 10,2% / 10,22% der Klasse). Die gemeldete Beteiligung weist kein alleiniges Stimm- oder Verfügungsrecht aus; gemeinsames Stimmrecht wird mit 4.958.998 und gemeinsames Verfügungsrecht mit 5.132.898 angegeben. In der Einreichung wird vermerkt, dass diese Aktien namensmäßig von Kunden der Wellington-Investmentberater gehalten werden, und der Vanguard Health Care Fund wird als die in Punkt 6 genannte Ausnahme identifiziert. Die Adresse des Emittenten und die Adressen der Einreicher sind enthalten; die Einreichung ist von Taisia Lowe am 08/05/2025 unterschrieben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Wellington discloses a material >5% position in IMCR (5.13M shares, ~10.2%), disclosed as shared voting/dispositive power.

The Schedule 13G/A shows Wellington and affiliated entities collectively beneficially own 5,132,898 Immunocore shares, representing roughly 10.2% of the class. Ownership is reported as held in the ordinary course for clients of Wellington investment advisers, with no sole voting or dispositive power reported and shared voting power of 4,958,998. This is a routine institutional disclosure for a substantial passive stake; it signals concentration of shareholder exposure but does not, on its face, indicate an intent to influence control per the filer’s certification.

TL;DR: Material passive stake disclosed; structure shows shared control across Wellington entities, with formal certification of non-control intent.

The filing identifies multiple Wellington entities (HC and IA classifications) and documents the ownership chain and adviser relationships. The certification states holdings are "in the ordinary course of business" and not held to change or influence control. For governance monitoring, the >5% disclosure is material for investor relations and proxy considerations, but the filing asserts passive intent and reports no sole voting or dispositive authority.

Deposito: Schedule 13G/A (Emendamento n. 5) relativo a Immunocore Holdings plc (CUSIP 45258D105).

Fatti principali: Wellington Management Group LLP e entità affiliate dichiarano la detenzione effettiva di 5.132.898 azioni di Immunocore common stock (riportate come 10,2% / 10,22% della classe). La proprietà dichiarata non indica potere di voto o di disposizione esclusivo; il potere di voto condiviso è indicato come 4.958.998 e il potere di disposizione condiviso come 5.132.898. La segnalazione precisa che queste azioni sono intestate a clienti dei consulenti d'investimento di Wellington e identifica il Vanguard Health Care Fund come eccezione citata nell'Elemento 6. Sono incluse le indirizzi dell'emittente e dei soggetti che presentano il documento; il deposito è firmato da Taisia Lowe in data 08/05/2025.

Presentación: Schedule 13G/A (Enmienda n.º 5) relativa a Immunocore Holdings plc (CUSIP 45258D105).

Datos clave: Wellington Management Group LLP y entidades afiliadas informan la propiedad beneficiaria de 5.132.898 acciones de las acciones ordinarias de Immunocore (reportadas como 10,2% / 10,22% de la clase). La propiedad declarada no muestra poder exclusivo de voto ni de disposición; se informa poder de voto compartido de 4.958.998 y poder de disposición compartido de 5.132.898. La presentación indica que estas acciones están registradas a nombre de clientes de los asesores de inversión de Wellington y identifica a Vanguard Health Care Fund como excepción referida en el Punto 6. Se incluyen las direcciones del emisor y de los presentadores; la presentación está firmada por Taisia Lowe el 08/05/2025.

제출: Schedule 13G/A (Amendment No. 5) — Immunocore Holdings plc에 대한 신고 (CUSIP 45258D105).

주요 사항: Wellington Management Group LLP 및 계열사는 Immunocore 보통주 5,132,898주를 실질적으로 보유하고 있다고 보고(해당 등급의 10.2% / 10.22%로 보고됨). 보고된 보유는 단독 의결권 또는 단독 처분권이 없음을 표시하며, 공동 의결권은 4,958,998주, 공동 처분권은 5,132,898주로 보고됩니다. 제출서에는 이 주식들이 웰링턴 투자 자문사의 고객 명의로 등기되어 있다고 기재되어 있으며, Item 6에 언급된 예외로 Vanguard Health Care Fund가 식별되어 있습니다. 발행인 주소 및 제출인 주소가 포함되어 있고; 제출서는 Taisia Lowe가 08/05/2025에 서명했습니다.

Dépôt : Schedule 13G/A (Amendement n° 5) concernant Immunocore Holdings plc (CUSIP 45258D105).

Faits clés : Wellington Management Group LLP et entités affiliées déclarent une participation bénéficiaire de 5 132 898 actions d'actions ordinaires d'Immunocore (déclarée comme 10,2% / 10,22% de la catégorie). La participation déclarée n'indique aucun pouvoir exclusif de vote ni de disposition ; le pouvoir de vote partagé est indiqué à 4 958 998 et le pouvoir de disposition partagé à 5 132 898. Le dépôt précise que ces actions sont inscrites au nom de clients des conseillers en investissement de Wellington et identifie le Vanguard Health Care Fund comme exception mentionnée à l'Item 6. Les adresses de l'émetteur et des déclarants sont incluses ; le dépôt est signé par Taisia Lowe le 08/05/2025.

Einreichung: Schedule 13G/A (Amendment Nr. 5) für Immunocore Holdings plc (CUSIP 45258D105).

Wesentliche Angaben: Wellington Management Group LLP und verbundene Einheiten melden wirtschaftliches Eigentum an 5.132.898 Aktien der Immunocore-Stammaktien (angegeben als 10,2% / 10,22% der Klasse). Die gemeldete Beteiligung weist kein alleiniges Stimm- oder Verfügungsrecht aus; gemeinsames Stimmrecht wird mit 4.958.998 und gemeinsames Verfügungsrecht mit 5.132.898 angegeben. In der Einreichung wird vermerkt, dass diese Aktien namensmäßig von Kunden der Wellington-Investmentberater gehalten werden, und der Vanguard Health Care Fund wird als die in Punkt 6 genannte Ausnahme identifiziert. Die Adresse des Emittenten und die Adressen der Einreicher sind enthalten; die Einreichung ist von Taisia Lowe am 08/05/2025 unterschrieben.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/05/2025
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/05/2025
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/05/2025
Wellington Management Company LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/05/2025
Immunocore Holdings Plc

NASDAQ:IMCR

IMCR Rankings

IMCR Latest News

IMCR Latest SEC Filings

IMCR Stock Data

1.68B
47.44M
5.08%
98.18%
17.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United Kingdom
OXFORDSHIRE